Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

If the influenza virus infecting cattle workers starts a pandemic, help in the form of a vaccine is months away ...

The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

The US government has signed a $176 million deal with Moderna to develop an mRNA-based pandemic influenza vaccine, as reports emerge of a fifth human case of H5N1 flu linked to ongoing outbreaks ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.